Brian Carlin, MD, FCCP, Discusses Challenges in Reducing Readmission Rates

Brian Carlin, MD, FCCP, Allegheny General Hospital, discusses the challenges in reducing 30-day readmission rates, specifically as they apply to congestive heart failure, pneumonia, and COPD. The biggest challenge of all is setting up a coordinated team care effort, says Dr Carlin.

Related Videos

Related Content

Advertisement

June 25th 2025

Solrikitug Shows Promise as Next-Generation Anti-TSLP Therapy in Asthma, COPD

Hayden E. Klein

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 20th 2025

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

Julia Bonavitacola Colleen Kelley, MD, MPH

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

June 19th 2025

Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

Julia Bonavitacola Onyema Ogbuagu, MBBCh, FACP, FIDSA

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

Related Content

Advertisement

June 25th 2025

Solrikitug Shows Promise as Next-Generation Anti-TSLP Therapy in Asthma, COPD

Hayden E. Klein

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 20th 2025

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

Julia Bonavitacola Colleen Kelley, MD, MPH

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

June 19th 2025

Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

Julia Bonavitacola Onyema Ogbuagu, MBBCh, FACP, FIDSA

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.